2016 PQRS

Inflammatory Bowel Disease (IBD)

Measures Group

New Jersey Innovation Institute
An NJIT Corporation

Measures

#110 Preventive Care and Screening: Influenza Immunization

#111 Pneumonia Vaccination Status for Older Adults

#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

#270 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy

#271 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment

#274 Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

#275 Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

Reporting Instructions

(1) Identify patients with the following criteria:

- Aged 18 years and older on date of encounter
- Encounter during January 1 - December 31, 2016 with the following:

  One of the following diagnosis codes indicating IBD:
  K50.00, K50.011, K50.012, K50.013, K50.014, K50.018, K50.019, K50.10, K50.111, K50.112, K50.113, K50.114, K50.118, K50.119, K50.80, K50.811, K50.812, K50.813, K50.814, K50.818, K50.819, K50.90, K50.911, K50.912, K50.913, K50.914, K50.918, K50.919, K51.00, K51.011, K51.012, K51.013, K51.014, K51.018, K51.019, K51.20, K51.211, K51.212, K51.213, K51.214, K51.218, K51.219, K51.30, K51.311, K51.312, K51.313, K51.314, K51.318, K51.319, K51.40, K51.411, K51.412, K51.413, K51.414, K51.418, K51.419, K51.50, K51.511, K51.512, K51.513, K51.514, K51.518, K51.519, K51.80, K51.811, K51.812, K51.813, K51.814, K51.818, K51.819, K51.90, K51.911, K51.912, K51.913, K51.914, K51.918, K51.919

  <u>and</u>

  One of the following patient encounter codes:
  99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99406, 99407

Need more information? Connect with NJII PQRS Registry
973-642-4055 • pqrs@njii.com • www.njii.com/pqrs

(2) Report all applicable measures within the measures group for at least 20 patients.

- The majority of the patients reported must be Medicare Part B Fee-for-service (FFS) patients, including Medicare Secondary and Railroad Medicare.
- For each measure, the measure's clinical performance must be satisfied for at least 1 patient. [Note: An asterisk (*) indicates that the measure's clinical performance is satisfied.]

For additional information or clinical rationale for measures, review the CMS Measure Specification for 2016 PQRS. All measures group Measure Specifications can be found on the NJII Member Portal > Registry > Getting Started section.

2016 PQRS

Inflammatory Bowel Disease (IBD)

Measures Group

New Jersey Innovation Institute
An NJIT Corporation

Patient Information

First Name | Middle Initial | Last Name | Date of Birth

Visit Date | Medical Record Number

Gender ◯ Male ◯ Female

Medicare FFS Patient ◯ Yes ◯ No

Select Measures Performance

* Recommended clinical performance satisfied
^ Patient is excluded from measure's performance

Select one (1) clinical action for each measure below, where applicable:

#110: Preventive Care and Screening: Influenza Immunization

Patients who received an influenza immunization OR who reported previous receipt of an influenza immunization.

For Visit Date 01/01/16-03/31/16: Report if Received 08/01/15-03/31/16

For Visit Date 10/01/16-12/31/16: Report if Received 08/01/16-12/31/16

- ◯ Administered or previously received*
- ◯ Not administered (Reason documented)^
- ◯ Not administered (No reason documented)

#111 Pneumonia Vaccination Status for Older Adults

Patients who have ever received a pneumococcal vaccination

- ◯ Administered or previously received*
- ◯ Not administered or previously received

New Jersey Innovation Institute
An NJIT Corporation

Select Measures Performance

#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation counseling intervention if identified as a tobacco user

- ◯ Identified as tobacco user and cessation intervention performed*
- ◯ Screened for tobacco use and identified as non-user of tobacco*
- ◯ Not screened for tobacco use (Medical reason documented)^
- ◯ Identified as tobacco user and cessation intervention NOT performed
- ◯ Not screened for tobacco use (No reason documented)

#270 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy

Prescribed a corticosteroid sparing therapy (e.g., thiopurines, methotrexate, or biologic agents)

- ◯ Corticosteroid sparing therapy prescribed*
- ◯ No sparing therapy (Reason documented)^
- ◯ No sparing therapy, no reason specified (No reason documented)

#271 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment

Patients who have received dose of corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600mg prednisone or greater for all fills and who were documented for risk of bone loss during the reporting year or the pervious calendar year.

- ◯ Bone Loss assessment performed*
- ◯ Not receiving corticosteroid therapy^
- ◯ No Bone Loss assessment performed

Select Measures Performance

#274 Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

Patients who had TB screening performed and results interpreted, within 6 months prior to receiving a first course of anti-TNF therapy

- ◯ TB screening test performed and results interpreted*
- ◯ Patient not receiving a first course of anti-TNF therapy*
- ◯ Screening not performed (Reason Documented)^
- ◯ Screening NOT performed (No Reason Documented)

#275 Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

Patients who had HBV status assessed and results interpreted within one year prior to receiving a first course of anti-TNF therapy

- ◯ Hepatitis B Virus (HBV) status assessed and results interpreted within one year prior to receiving a first course of anti-TNF (tumor necrosis factor) therapy*
- ◯ Patient has documented immunity to hepatitis B and is receiving a first course of anti-TNF therapy*
- ◯ Hepatitis B Virus (HBV) status not assessed (Reason Documented)^
- ◯ Patient not receiving a first course of anti-TNF therapy^
- ◯ Hepatitis B Virus (HBV) status not assessed (No Reason Documented)